Engineering a novel asymmetric head-to-tail (HtT) 1+1 and 2+1 T cell bispecific antibody (TCB) platform with superior T cell killing compared to 1+1 bispecific IgG antibodies
Antibody Therapeutics · 2026-11-08
DOI: 10.1093/abt/tbag057 ↗Abstract
Abstract Background: The overall activity of T cell engaging bispecific antibodies (TCBs) is governed by an interplay of various factors including antigen density, binding epitope, affinity, and molecular geometry. Conventional 1+1 IgG-like-TCBs represent the most utilized format amongst approved TCBs and offer prolonged pharmacokinetics via silenced Fc domains. Nevertheless, head-to-tail (HtT) formats, such as the 2+1 TCBs, have gained interest more recently. Methods: Here, we systematically evaluated HtT configurations, including 1+1 one-armed (OA), 2+1 classical, and 2+1 inverted TCB formats, against standard 1+1 IgG-like TCBs across CEACAM5, FOLR1, MCSP, and CD20 as tumor antigens. Assessments included in vitro functional assays, in vivo humanized mouse models, and biophysical characterization via negative-stain transmission electron microscopy (NS-TEM) and liquid-state atomic force microscopy (AFM). Results: HtT geometries consistently outperformed standard 1+1 IgG-like TCBs in tumor cell lysis, T-cell activation, and tumor growth inhibition. Biophysical analyses confirmed that the 2+1 inverted format possesses exceptional conformational flexibility, behaving as freely jointed rigid segments. Crucially, by positioning the CD3-binding site internally, the 2+1 inverted format circumvents N-terminal steric restrictions of the tumor antigen binder, preserving high-avidity tumor engagement. Furthermore, in vivo evaluation demonstrated that the HtT configuration remains highly efficacious in combination with standard bivalent CD20 monoclonal antibodies. Conclusions: The asymmetric inverted configurations of TCBs represent a robust, versatile, and highly combinable platform for next-generation TCB design.
EUVIMED